We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+20.94%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.51B
AUM Growth
+$540M
Cap. Flow
-$18.6M
Cap. Flow %
-0.34%
Top 10 Hldgs %
46.25%
Holding
691
New
31
Increased
112
Reduced
426
Closed
60

Top Buys

Rank Stock Value
1
LITE icon
Lumentum
LITE
+$33.3M
2
BE icon
Bloom Energy
BE
+$30.1M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$25M
4
SNDK
Sandisk
SNDK
+$23.5M
5
NBIS
Nebius Group N.V.
NBIS
+$22.4M

Top Sells

Rank Stock Value
1
BTI icon
British American Tobacco
BTI
+$36.2M
2
CLS icon
Celestica
CLS
+$21.9M
3
WMT icon
Walmart Inc
WMT
+$21.5M
4
UNH icon
UnitedHealth
UNH
+$20.7M
5
YUMC icon
Yum China
YUMC
+$14.8M

Sector Composition

Rank Sector Weight
1 Technology 48.98%
2 Communication Services 15.81%
3 Consumer Discretionary 13.07%
4 Healthcare 6.06%
5 Consumer Staples 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
601
Allogene Therapeutics
ALLO
$680M
$5.92K ﹤0.01%
4,774
-594
-11% -$708
FHTX icon
602
Foghorn Therapeutics
FHTX
$278M
$5.83K ﹤0.01%
1,192
-232
-16% -$1.23K
RNAC icon
603
Cartesian Therapeutics
RNAC
$227M
$5.61K ﹤0.01%
549
-101
-16% -$1.14K
VYGR icon
604
Voyager Therapeutics
VYGR
$189M
$5.57K ﹤0.01%
1,193
-162
-12% -$586
NGNE icon
605
Neurogene
NGNE
$670M
$5.48K ﹤0.01%
316
-52
-14% -$1.04K
KYTX icon
606
Kyverna Therapeutics
KYTX
$455M
$5.39K ﹤0.01%
898
-172
-16% -$688
ENTA icon
607
Enanta Pharmaceuticals
ENTA
$378M
$5.36K ﹤0.01%
448
-77
-15% -$615
AVIR icon
608
Atea Pharmaceuticals
AVIR
$379M
$5.09K ﹤0.01%
1,754
-342
-16% -$1.17K
SLN
609
Silence Therapeutics
SLN
$549M
$5.08K ﹤0.01%
978
-187
-16% -$1.04K
CDXS icon
610
Codexis
CDXS
$159M
$4.74K ﹤0.01%
1,942
-77
-4% -$210
TRDA icon
611
Entrada Therapeutics
TRDA
$263M
$4.68K ﹤0.01%
807
-151
-16% -$883
IRWD icon
612
Ironwood Pharmaceuticals
IRWD
$614M
$4.44K ﹤0.01%
3,387
-584
-15% -$604
OABI icon
613
OmniAb
OABI
$288M
$4.14K ﹤0.01%
2,587
-512
-17% -$936
MXCT icon
614
MaxCyte
MXCT
$112M
$3.56K ﹤0.01%
2,256
-445
-16% -$773
CCCC icon
615
C4 Therapeutics
CCCC
$405M
$3.25K ﹤0.01%
1,463
-288
-16% -$691
TVGN icon
616
Tevogen Bio Holdings
TVGN
$28.4M
$3.21K ﹤0.01%
82
-2
-2% -$98
PEPG icon
617
PepGen
PEPG
$123M
$3.14K ﹤0.01%
679
-129
-16% -$208
NKTX icon
618
Nkarta
NKTX
$154M
$3.03K ﹤0.01%
1,463
-288
-16% -$591
FATE icon
619
Fate Therapeutics
FATE
$293M
$3.02K ﹤0.01%
2,396
-341
-12% -$368
PYXS icon
620
Pyxis Oncology
PYXS
$182M
$2.96K ﹤0.01%
1,334
-95
-7% -$137
CLYM
621
Climb Bio
CLYM
$692M
$2.93K ﹤0.01%
1,458
-158
-10% -$293
BMEA icon
622
Biomea Fusion
BMEA
$88.2M
$2.59K ﹤0.01%
1,280
+381
+42% +$698
MGNX icon
623
MacroGenics
MGNX
$240M
$2.19K ﹤0.01%
1,303
-254
-16% -$411
PLRX icon
624
Pliant Therapeutics
PLRX
$65.6M
$1.87K ﹤0.01%
1,264
-245
-16% -$374
TCRX icon
625
TScan Therapeutics
TCRX
$49.4M
$1.86K ﹤0.01%
1,020
-198
-16% -$351
23 24
25
26 27

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q3 2025 Portfolio in Review

As of Q3 2025, GF Fund Management held 691 positions worth $5.51B, up 11% from $4.97B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q3 2025 filing shows 31 new, 112 increased, 426 reduced and 60 closed positions. Its largest new stake was Bloom Energy: 648,856 shares worth $54.9M. The largest sale was British American Tobacco, an estimated $36.2M.

By sector, the portfolio is most concentrated in Technology at 49% of assets, up from 46% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q3 2025 buy was Bloom Energy: 648,856 shares worth $54.9M.
  • GF Fund Management added most to Lumentum in Q3 2025, an estimated $33.3M increase.
  • GF Fund Management's biggest Q3 2025 reduction was British American Tobacco, cutting an estimated $36.2M.
  • GF Fund Management fully exited Yum China in Q3 2025, selling an estimated $14.8M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.51B portfolio in Q3 2025.
  • GF Fund Management opened 31 new positions and closed 60 in Q3 2025.
  • GF Fund Management's portfolio value rose 11% quarter-over-quarter to $5.51B.

Based on GF Fund Management's 13F filing for Q3 2025, filed 7 Nov 2025.